Michael Ulz
Stock Analyst at Morgan Stanley
(3.70)
# 719
Out of 4,670 analysts
109
Total ratings
44.68%
Success rate
10.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Reiterates: Overweight | $49 | $7.01 | +599.00% | 10 | Oct 8, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Overweight | $105 | $52.59 | +99.66% | 2 | Sep 12, 2024 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $48 → $52 | $29.69 | +75.14% | 2 | Aug 14, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $12 → $11 | $10.41 | +5.67% | 6 | Aug 13, 2024 | |
| THRD Third Harmonic Bio | Upgrades: Overweight | $12 → $20 | $12.47 | +60.38% | 4 | Aug 9, 2024 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $110 → $115 | $94.15 | +22.15% | 9 | Jul 12, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $250 → $255 | $244.89 | +4.13% | 8 | Jul 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $53 → $57 | $44.73 | +27.43% | 3 | Jun 18, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $36 → $27 | $18.54 | +45.63% | 4 | May 13, 2024 | |
| KYTX Kyverna Therapeutics | Initiates: Overweight | $40 | $4.39 | +811.16% | 1 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $2.29 | +205.68% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $2.09 | +761.24% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $1 → $0.5 | $0.55 | -9.07% | 4 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $25 | $1.87 | +1,236.90% | 5 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $48 | $34.01 | +41.13% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $33 | $32.73 | +0.82% | 3 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $9.59 | +181.54% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $4 | $0.85 | +373.37% | 4 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $23 | $8.55 | +169.01% | 3 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $2.17 | +821.40% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $14.11 | +218.92% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.89 | +1,021.08% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $8 | $0.88 | +812.62% | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $2.47 | +21.46% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $7.12 | +321.35% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $8.89 | +237.46% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $8.32 | +440.87% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $2.04 | +880.39% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $47.24 | +69.35% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $9.66 | +55.28% | 3 | Jul 12, 2017 |
Silence Therapeutics
Oct 8, 2024
Reiterates: Overweight
Price Target: $49
Current: $7.01
Upside: +599.00%
Viking Therapeutics
Sep 12, 2024
Reiterates: Overweight
Price Target: $105
Current: $52.59
Upside: +99.66%
Dyne Therapeutics
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $29.69
Upside: +75.14%
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Underweight
Price Target: $12 → $11
Current: $10.41
Upside: +5.67%
Third Harmonic Bio
Aug 9, 2024
Upgrades: Overweight
Price Target: $12 → $20
Current: $12.47
Upside: +60.38%
Blueprint Medicines
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $110 → $115
Current: $94.15
Upside: +22.15%
Alnylam Pharmaceuticals
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $250 → $255
Current: $244.89
Upside: +4.13%
Mirum Pharmaceuticals
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $44.73
Upside: +27.43%
Arrowhead Pharmaceuticals
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $18.54
Upside: +45.63%
Kyverna Therapeutics
Mar 4, 2024
Initiates: Overweight
Price Target: $40
Current: $4.39
Upside: +811.16%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $2.29
Upside: +205.68%
Feb 27, 2024
Initiates: Overweight
Price Target: $18
Current: $2.09
Upside: +761.24%
Jan 5, 2024
Downgrades: Underweight
Price Target: $1 → $0.5
Current: $0.55
Upside: -9.07%
Nov 29, 2023
Maintains: Overweight
Price Target: $28 → $25
Current: $1.87
Upside: +1,236.90%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $34.01
Upside: +41.13%
Oct 11, 2023
Maintains: Overweight
Price Target: $70 → $33
Current: $32.73
Upside: +0.82%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $9.59
Upside: +181.54%
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $0.85
Upside: +373.37%
May 23, 2023
Maintains: Outperform
Price Target: $20 → $23
Current: $8.55
Upside: +169.01%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $2.17
Upside: +821.40%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $14.11
Upside: +218.92%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.89
Upside: +1,021.08%
Jan 27, 2023
Maintains: Equal-Weight
Price Target: $6 → $8
Current: $0.88
Upside: +812.62%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $2.47
Upside: +21.46%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $7.12
Upside: +321.35%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $8.89
Upside: +237.46%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $8.32
Upside: +440.87%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $2.04
Upside: +880.39%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $47.24
Upside: +69.35%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $9.66
Upside: +55.28%